Compare Globus Medical Inc. Class A Common Stock (GMED) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Snap Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Snap Inc trades at $6.05 (market cap $10.98B). The key difference: Globus Medical Inc. Class A Common Stock and Snap Inc are close in size by market cap, and Snap Inc is more actively traded (53,140,165 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Snap Inc for 68 Days on average.
| GMED | SNAP | |
|---|---|---|
Market Cap | $10.25B | $10.98B |
Volume | 1,108,124 | 53,140,165 |
Sector | Health | Media |
52-Week High | $96.82 | $9.09 |
52-Week Low | $58.33 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $9.76B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Snap Inc. (SNAP) trades at $6.10, down 6.73% over 24 hours, with technical indicators showing a bullish trend despite overbought RSI signals. The company reported revenue growth to $5.93B in 2025, though net losses persist at -$460M, with improving margins. Recent news highlights AI and AR developments, including SPECS glasses partnerships with NVIDIA and Salesforce, driving investor optimism amid regulatory pressures.
The outlook remains cautious; while analyst consensus is a $7.91 price target with 38% buy ratings, risks include sustained losses, high debt, and competitive threats. Upside hinges on monetizing AI innovations and achieving profitability, but volatility from sentiment shifts poses near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
